Summary

KEY FINDINGS
The North America surgical site infection control market is projected to grow with a CAGR of 4.27% over the forecast period of 2024-2032. The North America surgical site infection control market is experiencing notable growth, driven by various key factors.
MARKET INSIGHTS
The aftermath of the COVID-19 pandemic significantly increased the risk of infections among the population, heightening the probability of the spread of the novel coronavirus as well as hospital-acquired infections. This increased risk, coupled with the rising demand for various medical procedures, is expected to fuel the market’s expansion as healthcare facilities prioritize infection prevention.
REGIONAL ANALYSIS
The North America surgical site infection control market growth evaluation entails a detailed assessment of the United States and Canada. Surgical site infections (SSIs) are among the costliest of all hospital-acquired infections, accounting for approximately 20% of such infections. They occur in an estimated 2% to 5% of patients undergoing inpatient surgery, with an annual incidence in the United States ranging from 160,000 to 300,000 cases. The financial burden associated with SSIs is significant, with annual costs estimated between USD 3.5 billion and USD 10 billion. Additionally, the rising number of cataract surgeries is contributing to the market’s growth. In the United States alone, approximately three million cataract surgeries are performed annually, indicating a growing demand for effective infection control solutions in surgical procedures.
As the number of surgical procedures continues to rise in the United States, the prevention of SSIs has become increasingly critical. To address this, the National Healthcare Safety Network (NHSN), a web-based surveillance system managed by the Centers for Disease Control and Prevention (CDC), is utilized to track SSIs. The NHSN enables hospitals, dialysis centers, and other medical facilities to collect and report infection rates and key healthcare process measures, thereby promoting improved infection control measures. Consequently, the market for surgical site infection control solutions in the United States is experiencing growth due to the increasing emphasis on preventive measures.
On the other hand, in Canada, the healthcare system continues to face challenges in managing surgical site infections. Despite advancements in aseptic techniques, antibiotic prophylaxis, and minimally invasive surgical methods, healthcare-associated infections (HAIs) remain a significant concern, complicating recovery for many surgical patients. According to the Canadian Patient Safety Institute (CPSI), SSIs are the most common healthcare-associated infection among surgical patients, with 77% of patient deaths related to infections.
The Centers for Disease Control also notes that while there have been improvements in infection control practices, including enhanced operating room ventilation and sterilization methods, SSIs continue to be a major cause of morbidity, prolonged hospitalization, and mortality in Canada. This persistent challenge highlights the need for continued efforts in infection prevention and control, thereby influencing the growth of the surgical site infection control market in North America.
SEGMENTATION ANALYSIS
The North America surgical site infection control market segmentation includes procedure, type of infection, end-user, and product. The procedure segment is further classified into laparoscopy, orthopedic surgery, cardiovascular, obstetrics and gynecology, wound closure, plastic & reconstructive surgery, thoracic surgery, microvascular, urology, neurosurgery, and other procedures.
Laparoscopy is a minimally invasive surgical procedure used to treat diseases associated with abdominal or pelvic organs through small-sized incisions. Compared to traditional laparotomy, which requires larger incisions, laparoscopy offers significant advantages by utilizing magnified tele-images for better precision with surgical tools. Laparoscopic surgeries have gained popularity, especially in bariatric surgeries for weight reduction. The growing prevalence of obesity worldwide, coupled with an increasing preference for bariatric procedures, is driving the demand for laparoscopic surgeries. Instruments used in laparoscopy include needle drivers, trocars, bowel graspers, bipolar dissectors, biopsy forceps, laparoscopic scissors, and triangular endo-flex retractors.
Similarly, orthopedic surgery focuses on the treatment of the musculoskeletal system, addressing issues such as musculoskeletal trauma, bone degenerative diseases, sports injuries, tumors, and infections. Orthopedic surgical instruments encompass a wide range of devices, including arthroscopy devices (such as baskets, biopsy and grasping forceps, curettes, duckbill punches, hook probes, and meniscotomes), surgical drills, mallets, needle holders, retractors, Cobb elevators, Ragnell instruments, and bone tamps. The rising incidence of osteoarthritis, osteoporosis, and obesity has led to an increase in orthopedic surgeries globally, which, in turn, is driving the growth of the surgical site infection control market.
COMPETITIVE INSIGHTS
Some of the major companies operating in the North America surgical site infection control market are 3M Company, American Polyfilm, Ansell Ltd, etc.
3M Company (3M) is a diversified technology corporation with operations across multiple industries, including industrial, safety and graphics, electronics and energy, health care, and consumer markets. Headquartered in Saint Paul, Minnesota, the company maintains a global presence, serving regions such as the United States, Europe, the Middle East, and Africa (EMEA), and the Asia-Pacific.
3M’s business is organized into five main segments: Industrial, Safety and Graphics, Health Care, Electronics and Energy, and Consumer. Moreover, 3M also develops and manufactures advanced technical ceramics designed for demanding applications in automotive, oil and gas, solar energy, industrial, electronics, and defense industries.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. HIGH EMPHASIS ON ENVIRONMENTAL HYGIENE BOOSTS THE SSI CONTROL MARKET
2.5.2. DISPOSABLE AND SINGLE-USE PRODUCTS ARE SHAPING THE SURGICAL INFECTION CONTROL LANDSCAPE
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGE IN GERIATRIC POPULATION
3.1.2. INCREASED INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
3.1.3. IMPLEMENTATION OF REGULATORY GUIDELINES FOR THE PREVENTION OF HOSPITAL-ACQUIRED INFECTIONS
3.2. KEY RESTRAINTS
3.2.1. LACK OF AWARENESS ASSOCIATED WITH HOSPITAL-ACQUIRED INFECTIONS
3.2.2. SURGING MEDICAL WASTE DUE TO THE USE OF MEDICAL DISPOSABLE ITEMS
3.2.3. RISING USE OF OUTPATIENT TREATMENTS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RISING RATE OF SURGICAL PROCEDURES
4.1.2. EXPANSION OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
4.1.3. ADVANCEMENTS IN TECHNOLOGY FOR PREVENTING SURGICAL SITE INFECTIONS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTIONS
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING FOR UNITED STATES
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
5. MARKET BY PROCEDURE
5.1. LAPAROSCOPY
5.2. ORTHOPEDIC SURGERY
5.3. CARDIOVASCULAR
5.4. OBSTETRICS AND GYNECOLOGY
5.5. WOUND CLOSURE
5.6. PLASTIC & RECONSTRUCTIVE SURGERY
5.7. THORACIC SURGERY
5.8. MICROVASCULAR
5.9. UROLOGY
5.10. NEUROSURGERY
5.11. OTHER PROCEDURES
6. MARKET BY TYPE OF INFECTION
6.1. SUPERFICIAL INCISIONAL SSI
6.2. DEEP INCISIONAL SSI
6.3. ORGAN OR SPACE SSI
7. MARKET BY END-USER
7.1. HOSPITALS
7.2. AMBULATORY SURGICAL CENTERS
8. MARKET BY PRODUCT
8.1. DISINFECTANTS
8.1.1. SKIN DISINFECTANTS
8.1.2. HAND DISINFECTANTS
8.2. MANUAL REPROCESSORS SOLUTIONS
8.3. SURGICAL DRAPES
8.4. SURGICAL GLOVES
8.5. SKIN PREPARATION SOLUTIONS
8.6. SURGICAL IRRIGATION
8.7. SURGICAL SCRUBS
8.8. HAIR CLIPPERS
8.9. MEDICAL NONWOVENS
8.10. OTHER PRODUCTS
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. NORTH AMERICA SURGICAL SITE INFECTION CONTROL MARKET DRIVERS
9.1.3. NORTH AMERICA SURGICAL SITE INFECTION CONTROL MARKET CHALLENGES
9.1.4. KEY PLAYERS IN NORTH AMERICA SURGICAL SITE INFECTION CONTROL MARKET
9.1.5. COUNTRY ANALYSIS
9.1.5.1. UNITED STATES
9.1.5.1.1. UNITED STATES SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.1.5.2. CANADA
9.1.5.2.1. CANADA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PARTNERSHIPS & AGREEMENTS
10.1.3. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. 3M COMPANY
10.2.1.1. COMPANY OVERVIEW
10.2.1.2. PRODUCTS
10.2.1.3. STRENGTHS & CHALLENGES
10.2.2. AMERICAN POLYFILM
10.2.2.1. COMPANY OVERVIEW
10.2.2.2. PRODUCTS
10.2.2.3. STRENGTHS & CHALLENGES
10.2.3. ANSELL LTD
10.2.3.1. COMPANY OVERVIEW
10.2.3.2. PRODUCTS
10.2.3.3. STRENGTHS & CHALLENGES
10.2.4. BECTON, DICKINSON AND COMPANY (BD)
10.2.4.1. COMPANY OVERVIEW
10.2.4.2. PRODUCTS
10.2.4.3. STRENGTHS & CHALLENGES
10.2.5. BELIMED AG
10.2.5.1. COMPANY OVERVIEW
10.2.5.2. PRODUCTS
10.2.5.3. STRENGTHS & CHALLENGES
10.2.6. BIOMERIEUX SA
10.2.6.1. COMPANY OVERVIEW
10.2.6.2. PRODUCTS
10.2.6.3. STRENGTHS & CHALLENGES
10.2.7. GAMA HEALTHCARE
10.2.7.1. COMPANY OVERVIEW
10.2.7.2. PRODUCTS
10.2.7.3. STRENGTHS & CHALLENGES
10.2.8. GETINGE AB
10.2.8.1. COMPANY OVERVIEW
10.2.8.2. PRODUCTS
10.2.8.3. STRENGTHS & CHALLENGES
10.2.9. JOHNSON & JOHNSON
10.2.9.1. COMPANY OVERVIEW
10.2.9.2. PRODUCTS
10.2.9.3. STRENGTHS & CHALLENGES
10.2.10. KIMBERLY-CLARK
10.2.10.1. COMPANY OVERVIEW
10.2.10.2. PRODUCTS
10.2.10.3. STRENGTHS & CHALLENGES
10.2.11. SOTERA HEALTH LLC
10.2.11.1. COMPANY OVERVIEW
10.2.11.2. PRODUCTS
10.2.11.3. STRENGTHS & CHALLENGES
10.2.12. STERIS CORPORATION
10.2.12.1. COMPANY OVERVIEW
10.2.12.2. PRODUCTS
10.2.12.3. STRENGTHS & CHALLENGES
10.2.13. STRYKER CORPORATION
10.2.13.1. COMPANY OVERVIEW
10.2.13.2. PRODUCTS
10.2.13.3. STRENGTHS & CHALLENGES